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Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia
syndrome characterized by episodic ventricular tachycardia induced by adrenergic stress. Although
b-blockers are used as ﬁrst-line therapy, their therapeutic effects are largely incomplete. Flecainide has
recently been shown to modify the molecular defects in CPVT. The aim of this study was to investigate
the effects of ﬂecainide as an add-on to conventional therapy on exercise-induced ventricular
arrhythmia and compare them with those of conventional therapy alone.
Methods: The study included 5 CPVT patients with a mutation in RYR2. They experienced episodic
arrhythmic events despite conventional b-blocker therapy and were therefore given ﬂecainide in
addition. The effects of the addition of ﬂecainide therapy on ventricular arrhythmia during exercise
testing were compared with those of conventional therapy alone.
Results: Both b-blockers alone and with additional ﬂecainide increased the maximal workload attained
at the onset of ventricular arrhythmia; however, only ﬂecainide increased the sinus rate at the onset of
ventricular arrhythmias. Furthermore, ﬂecainide increased the exercise capacity by preventing
exercise-induced arrhythmias. During a follow-up period of 1772 months, 1 patient experienced
recurrent arrhythmic episodes that were associated with noncompliance. All patients reported
improvements in their ability to perform the activities of daily living.
Conclusion: Flecainide effectively reduced ventricular arrhythmias via a mechanism that differs from
that of b-blockers in genotype-positive patients with CPVT. The speciﬁc effects of ﬂecainide may be
critical in the improvement noted in the patients’ ability to perform daily activities.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
is an inherited arrhythmia syndrome. Mutations in 3 genes have
been identiﬁed as causative factors for CPVT: RYR2, encoding the
cardiac ryanodine receptor (RyR2); CASQ2, encoding cardiac calse-
questrin; and KCNJ2, encoding the inward rectiﬁer potassiumrt Rhythm Society. Published by E
: þ81 77 543 5839.
orie).channel [1–5]. CPVT is characterized by bi-directional and/or
polymorphic ventricular tachycardias induced by adrenergic stress
in the absence of structural heart disease and is associated with a
high incidence of sudden cardiac death [6–8].
Within the vast therapeutic arsenal of antiarrhythmic agents,
b-blockers have been proven to reduce ventricular arrhythmias
and improve mortality rates in CPVT patients [1,6–9]. Although
implantable cardioverter deﬁbrillators (ICDs) are used to prevent
sudden death [10], painful shocks can increase the sympathetic
tonus and trigger further arrhythmias, eventually leading to a
malignant cycle of ICD shocks and, ultimately, death in patientslsevier B.V. All rights reserved.
Table 1
Patient characteristics and therapy.
Patient
no.
Family
no.
Mutation
in RYR2
Sex Age at
ﬁrst
symptom
(yr)
Presenting
symptom
Age at
diagnosis
(yr)
Aborted
cardiac
arrest
ICD Conventional
therapy, mg
(mg/kg body
weight)
Presenting
symptom
before
ﬂecainide
Age at treatment
with additional
ﬂecainide (yrs)
Final drug dosage, mg
(mg/kg body weight)
Flecainide Conventional
therapy
1 1 I4587V F 15 Syncope 37 No Yes Metoprolol 120
(2.36)
Dyspnea 38 100 (1.96) Metoprolol
60 (1.18)
2 1 I4587V M 11 Syncope 11 Yes No Metoprolol 40
(1.03)
Syncope 13 100 (2.1) Metoprolol
40 (1.03)
3 2 R2474G F 1 Syncope 11 Yes Yes Atenolol 100
(3.2) Verapamil
120 (3.9)
Syncope 18 150 (4.8) Atenolol 100
(3.2)
Verapamil
120 (3.9)
4 3 R407S M 12 Syncope 13 No Yes Atenolol 100
(2.22) Verapamil
120 (2.67)
Dyspnea 13 100 (2.22) Atenolol 50
(1.11)
5 4 G2400T M 3 Syncope 15 Yes No Atenolol 50
(0.97)
Syncope 15 200 (3.86) Atenolol 50
(0.97)
ICD, implantable cardioverter deﬁbrillator.
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development of additional therapies to suppress ventricular
arrhythmias is highly desirable. Flecainide, a class I sodium
channel blocker, has recently been reported to block the RyR2
channel and prevent CPVT episodes [13–15]. However, the dif-
ference between b-blockers and ﬂecainide in terms of their
respective therapeutic effects in preventing CPVT episodes is yet
to be investigated in detail. In the present study, we examined the
effectiveness of adding ﬂecainide to b-blocker treatment in
inhibiting exercise-induced arrhythmias in CPVT patients with
RYR2 mutations.2. Methods
2.1. Patients and study design
Japanese probands and their relatives with a clinical diagnosis
of CPVT (based on exercise-induced bidirectional and/or poly-
morphic VT in the absence of structural cardiac disease) and a
putative pathogenic RYR2 mutation were enrolled in the study.
Because the effects of conventional therapy with the maximum
tolerable dose of b-blockers with or without verapamil were
insufﬁcient, all patients in this study were treated with ﬂecainide.
The dose of ﬂecainide was adjusted according to the highest
tolerable dose at the discretion of the treating physicians. Patients
treated with ﬂecainide were followed up at our outpatient clinic
every 1–2 months. This study was approved by the institutional
review boards at each of the participating institutions.
2.2. Effects of ﬂecainide
Exercise testing using the standard Bruce protocol was per-
formed under 3 conditions: in the absence of any medication,
with b-blocker therapy, and with b-blocker therapy and ﬂecai-
nide. Patients underwent exercise testing after receiving treat-
ment for more than 2 weeks. The dosage of each drug for each
patient is shown in Table 1. Exercise testing was repeated as per
the same protocol until at least the workload equivalent to that
achieved during the previous test was attained, so long as no
severe symptoms requiring termination of exercise were noted.
The end-point of the exercise test was attainment of the target
heart rate, occurrence of frequent premature ventricular ectopy
(PVE), non-sustained VT, leg fatigue, or dyspnea. The numbers of
PVEs (i.e., isolated PVE, bigeminal rhythm of PVE, bidirectional VT,polymorphic VT, and VT [sustained or non-sustained]) were
counted. Sinus heart rate at the onset of ventricular arrhythmias
was calculated from the last sinus RR interval. Ventricular
arrhythmias were scored as described previously [15]: 1, no or
isolated PVE; 2, bigeminal PVE and/or frequent PVE (410 per
min); 3, couplet; and 4, non-sustained VT (43 successive PVEs).
A ventricular arrhythmia score of 1 was considered as complete
suppression of ventricular arrhythmias, whereas other improve-
ments in the ventricular arrhythmia score were considered partial
suppression. Patients were followed up for arrhythmia recur-
rences at our outpatient clinic every 1–2 months.
2.3. Statistical analysis
Continuous data are presented as mean7standard deviation
or median (range), and categorical variables are presented as
number (percentage). Related samples were compared using the
paired Wilcoxon signed-rank test for continuous and ordinal
variables and the McNemar test for dichotomous variables. A
two-tailed P value of o0.05 was considered statistically signiﬁ-
cant. Statistical analysis was performed using JMP version 7.0.1
(SAS Campus Drive, Building T, Cary, NC, USA).3. Results
3.1. Patient characteristics
Five genotype-positive CPVT patients from 4 families were
administered ﬂecainide therapy in addition to conventional ther-
apy (Table 1). Patient 2 was the son of patient 1. Data on patient
3 have also been reported elsewhere [15]. Two patients were
female. The mean age at the ﬁrst CPVT episode was 876 years
(range, 1–15 years). Prior to treatment with ﬂecainide, all patients
had experienced ventricular arrhythmias and/or symptoms
induced by physical or emotional stress, despite the use of max-
imum tolerable doses of b-blockers with or without verapamil.
Flecainide was started at the age of 19711 years (range, 13–38
years). After the addition of ﬂecainide, the dosage of conventional
therapy was modiﬁed in patients 1 (reduction of b-blocker dosage)
and 4 (reduction of b-blocker dosage and discontinuation of
verapamil) because of sinus bradycardia. It should be noted that
ﬂecainide caused no side effects in any of the patients enrolled in
this study. Flecainide prolonged the PR interval (from 138723 ms
without ﬂecainide to 163713 ms with ﬂecainide; Po0.05), but did
K. Dochi et al. / Journal of Arrhythmia 29 (2013) 255–260 257not affect the QRS duration (8276ms without ﬂecainide and
8077 ms with ﬂecainide; P¼0.68) or the corrected QT interval
(389727 ms without ﬂecainide and 394740 ms with ﬂecainide;
P¼0.79). The values for these parameters remained within the
normal range at rest and during exercise testing in all patients.3.2. Effects of ﬂecainide during exercise testing
Exercise testing was performed at baseline without the use of
any medication, on conventional therapy with b-blockers, and
after the addition of ﬂecainide to conventional therapy. Patients
4 and 5 did not undergo baseline exercise testing because severe
arrhythmic events were easily induced in these patients. Exercise
testing was repeated as per the same protocol until at least the
workload attained in the previous test was achieved in all
patients. We initially studied the effects of b-blockers on
exercise-induced ventricular arrhythmias in 3 patients who had
undergone baseline testing (patients 1–3) (Fig. 1). b-Blockers
decreased the frequency of PVE in 1 patient, but did not suppress
VT in the remaining 2 (Fig. 1). b-blockers reduced the heart rate in
response to exercise compared to the baseline values obtained
without the administration of any medication and also sup-
pressed the incidence of PVE during exercise in cases that showed
PVE during baseline testing. However, the use of b-blockers did
not result in any notable changes in the maximum number of
PVEs observed compared to that observed during baseline testing.
Furthermore, the sinus rate at the onset of PVE was identical at
baseline testing and with the use of b-blockers.
We then studied the effects of adding ﬂecainide to conventional
therapy on exercise-induced ventricular arrhythmias in 5 patientsFig. 1. Ventricular arrhythmias during exercise testing without any drug therapy and
premature ventricular ectopies (PVEs) in every minute are shown for 3 patients who u
patient 3). The ﬁnal point for HR indicates the end of exercise. Asterisks indicate the o(Fig. 2). Flecainide suppressed VT in 3 patients (patients 1–3),
including 1 (patient 3) in whom ﬂecainide completely suppressed
ventricular arrhythmias (Fig. 2). In the remaining 2 patients (patients
4 and 5), although ﬂecainide did not result in any changes in the
ventricular arrhythmia scores (Fig. 3), the drug effectively increased
the exercise workload at the onset of ventricular arrhythmias.
Furthermore, ﬂecainide improved the maximum workload attained
in 3 patients (Table 2). During exercise testing after treatment with
ﬂecainide, ventricular arrhythmias developed at a later stage and the
sinus rate at the onset of ventricular arrhythmias increased in
comparison to the observations made during exercise testing after
treatment with conventional therapy alone in all patients except for
1, who did not have ventricular arrhythmias while on treatment with
ﬂecainide (Table 2). Interestingly, the response in terms of heart rate
to exercise stress was similar for treatment with conventional therapy
alone and that with additional ﬂecainide, despite the favorable effects
of ﬂecainide observed in 2 patients (Fig. 3, patients 2 and 4).3.3. Clinical follow-up
During a followup of 1772 months (range, 15–20 months),
4 patients who received a combination of ﬂecainide with con-
ventional therapy did not develop recurrences of arrhythmias.
Patient 2 did not develop arrhythmias for 17 months after the
addition of ﬂecainide; however, arrhythmic events later devel-
oped because of noncompliance with the prescribed treatment
regimens. This patient was immediately administered therapy
and did not experience any further events. Notably, all patients
reported improvements in their ability to perform activities of
daily living after the addition of ﬂecainide at their follow-upwith conventional therapy. Sinus heart rate (HR) and the number of instances of
nderwent exercise testing without any drug therapy (A, patient 1; B, patient 2; C,
ccurrence of ventricular tachycardia.
Fig. 2. Effects of ﬂecainide in addition to conventional therapy on exercise-induced ventricular arrhythmias. Sinus heart rate (HR) and the number of instances of
premature ventricular ectopies (PVEs) were compared between treatment with conventional therapy alone and treatment with ﬂecainide in addition to conventional
therapy. Asterisks indicate the occurrence of ventricular tachycardia (A, patient 1; B, patient 2; C, patient 3; D, patient 4; E, patient 5).
Fig. 3. Ventricular arrhythmia score during exercise testing with conventional
therapy alone and with ﬂecainide in addition to conventional therapy. PVE,
premature ventricular ectopy; NSVT, non-sustained ventricular tachycardia.
K. Dochi et al. / Journal of Arrhythmia 29 (2013) 255–260258visits. All patients showed good tolerance to ﬂecainide, and none
developed severe side effects.4. Discussion
The present study showed that ﬂecainide suppresses CPVT in a
manner that differs from that of b-blockers. Although ﬂecainideincreased the sinus rate at the onset of ventricular arrhythmias,
b-blockers failed to demonstrate such a change, despite the fact
that both ﬂecainide and b-blockers increased the exercise work-
loads at the onset of ventricular arrhythmias. Furthermore, ﬂecai-
nide facilitated increased exercise capacity by preventing PVE and
improved the performance of activities of daily living. Conse-
quently, this considerably ameliorated the patient’s quality of life.
Because ventricular tachyarrhythmias are induced by adrenergic
stress in patients with CPVT, anti-adrenergic therapy—primarily
achieved by the use of b-blockers—has been widely used to
suppress CPVT [6–9,16]. Unfortunately, the effect of b-blockers on
suppressing recurrences of ventricular tachyarrhythmias is ulti-
mately incomplete [7,8]. In the present study, b-blockers reduced
the response in terms of heart rate to exercise and increased the
exercise workload at the onset of ventricular arrhythmias, which
could be attributed to the anti-adrenergic properties of the drug, but
failed to increase heart rate at the onset of arrhythmias. In contrast,
ﬂecainide increased the heart rate at the onset of arrhythmias
during exercise testing and suppressed ventricular arrhythmias even
at higher heart rates, suggesting that this unique action may be
crucial in the suppression of CPVT.
Spontaneous Ca2þ release from the destabilized RyR2 complex
in the sarcoplasmic reticulum triggered by adrenergic stress is the
mechanism underlying CPVT [17–19], and thus, the suppression of
spontaneous Ca2þ release could potentially be of therapeutic value
for CPVT. Flecainide was recently shown to directly reduce the
probability of RyR2 channels being open in the sarcoplasmic
reticulum, thereby suppressing triggered beats [13,14]. The drug
also decreases the activity of Naþ/Ca2þ-exchangers via inhibition of
the Naþ channel, which in turn reduces intracellular Ca2þ overload
and thereby the rate of triggered beats [13,14]. Furthermore,
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K. Dochi et al. / Journal of Arrhythmia 29 (2013) 255–260 259ﬂecainide increases the inward rectiﬁer Kþ current generated by
Kir2.1 channels by reducing their afﬁnity for intracellular polya-
mines and stabilizes the resting membrane potential, resulting in
the suppression of triggered activity [20]. These multiple effects of
ﬂecainide may explain the mechanism by which the drug effectively
prevents ventricular arrhythmias even at higher sinus rates during
exercise and thus increases the heart rate at the onset of ventricular
arrhythmias.5. Study limitations
Although the number of CPVT patients enrolled in the present
study was small, we documented clearly discernible effects of
ﬂecainide on CPVT during exercise testing. The dose of ﬂecainide
was adjusted to increase it to the maximum tolerable dose without
monitoring serum concentrations. We studied the effects of ﬂecai-
nide in combination with conventional therapy in patients whose
arrhythmias were uncontrolled on treatment with conventional
therapy. The effect of ﬂecainide was evaluated by exercise testing,
as was done in previous studies, and the reproducibility of the
effects of ﬂecainide during exercise testing has been reported
[7,15]. However, variability in exercise test results cannot be
completely ignored and exercise testing may not accurately predict
the occurrence of fatal arrhythmic events [7]. Exercise testing prior
to the initiation of conventional therapy was not performed for
2 patients whose severe arrhythmic events were easily induced.
The aim of this study was to compare the efﬁcacy of conventional
therapy and the addition of ﬂecainide on exercise-induced ven-
tricular arrhythmias.6. Conclusion
Flecainide showed multiple pharmacological effects—some of
which differ from those of b-blockers—in patients with CPVT. The
unique effects of ﬂecainide may explain the favorable changes
noted in patients whose arrhythmias were refractory to conven-
tional therapy. Flecainide was also effective in increasing exercise
capacity at the onset of ventricular arrhythmias, which is assumed
to be a crucial factor in the improvement documented in the
patients’ overall quality of life.Conﬂict of interest
The authors indicated no potential conﬂict of interest.
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